A phase I study of combination of intravenous gemcitabine, oxaliplatin, and 5-FU with daily oral thalidomide (GOFT) in metastatic/locally advanced pancreatic carcinoma patients. [electronic resource]
Producer: 20080314Description: 2141-5 p. digitalISSN:- 0172-6390
- Aged
- Angiogenesis Inhibitors -- administration & dosage
- Antimetabolites, Antineoplastic -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Deoxycytidine -- administration & dosage
- Drug Therapy, Combination
- Female
- Fluorouracil -- administration & dosage
- Humans
- Infusions, Intravenous
- Liver Neoplasms -- secondary
- Male
- Maximum Tolerated Dose
- Middle Aged
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Pancreatic Neoplasms -- drug therapy
- Thalidomide -- administration & dosage
- Tomography, X-Ray Computed
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.